GEN Exclusives

More »

Feature Articles

More »
Jun 1, 2011 (Vol. 31, No. 11)

Streamlining Nucleic Acid Sample Prep

Advances in Long-Read Technology, Target Enrichment, and Collection Reshape Operations

  • Micro-Size Me

    Click Image To Enlarge +
    In order to eliminate much of the background DNA that interferes with its de novo pathogen detection work, Sandia National Laboratory researchers use a two-pronged approach that includes exome capture beads and a normalization process to get rid of high-abundance DNA.

    Research into de novo pathogen detection at the Sandia National Laboratory utilizes more conventional molecular biological principles, but a less-than-conventional platform, to enrich nucleic acids.

    Unlike PCR- and other probe-based technologies, next-gen (and next-next-gen) sequencing doesn’t require advanced knowledge of the target sequence. You read the entire genetic code and then use phylogenetics and the like to categorize and classify. Yet with human DNA and background flora and fauna DNA in the mix, finding pathogen DNA in matrices such as nasopharyngeal swabs is like looking for “a needle in a haystack,” said senior scientist Kamlesh (Ken) Patel.

    Patel’s team uses a two-pronged approach to eliminate much of the background DNA (like housekeeping genes) that take up sequencer bandwidth, he explained. Exome capture beads “pull out all the human things we don’t care about and remove them from the supernatant.”

    They also use a normalization process to get rid of high-abundance DNA: DNA is denatured and allowed to re-anneal for a set time. Higher abundance sequences will find their complement faster than the rare fractions—similar to a C0t analysis. The double-stranded DNA is then either digested or separated out from the remaining single strands (among which the rare pathogen DNA would lie) using hydroxyapatite.

    All this is done on an automated miniaturized platform. Digital microfluidics manipulate single-digit microliter volume droplets by altering the voltage at each square of the platform, allowing reagents to be brought to the sample, and the sample itself to move to different squares. The device is connected with various lab-on-a-chip modules, such as a capillary tube-based heated microreactor, by means of a syringe pump.

    The platform manages reactions at a scale and concentration that can directly interface with an Illumina flow cell. “We’re technically sequencer-agnostic,” Patel said. The firm has focused on Illumina first, he explained, because of its familiarity and also its collaborators.

    Because the interfaces are flexible, “we can change pretty quickly if we need to do a different type of protocol.”

  • Respiratory Diseases

    Sometimes gathering nucleic acids for identification of pathogens is done in more mundane ways. Current practice for tuberculosis and other lung ailment diagnostics requires sputum, which is difficult to collect and often contaminated by saliva. A nebulizer may be needed to aid patients unable to produce sputum normally, while in some cases a bronchoalveolar lavage is required.

    Deton engineered a small device to collect intact bacterial aerosols that are coming out of a cough. “The sample can be extracted from the device and sent to the lab, just the way it’s being sent right now,” said principal Patrick Sislian. “But instead of sputum it would be in a buffered solution: more concentrated than sputum, and without having those negatives that the sputum samples would.” The instrument looks similar to CPAP masks used for sleep apnea, connected to a palm-sized box with a liquid-filled chamber where the samples are collected. It is designed to be extremely simple to use, completely disposable, and powered by a lab vacuum. With a projected price point of about $250—less than that of a nebulizer treatment—Sislian thinks the Deton device “would have the economic and the practical advantage” over current practice.

    He expects the prototype to undergo testing on a few patients within several months, with a larger patient study further down the road.

    As part of his chemical engineering doctoral training at UCLA, Sislian studied the use of aerodynamic shock to lyse both bacterial spores and vegetative cells, and created a prototype device that he ultimately hopes to integrate into the cough analyzer. “We’re also looking for people to partner with on the biosensor side,” to integrate nucleic-acid testing into the device as well.

  • Mash It Up

    Click Image To Enlarge +
    According to Bertin Technologies, Precellys 24 combines speed and efficiency to grind, homogenize, and lyse a range of sample types.

    Bertin Technologies’ way of breaking down cells is “not really innovative,” confessed Quitterie Brossard-Desjonqueres, the company’s lab equipment marketing manager. “The shock between tubes, sample, and beads will grind the sample. It’s quite a simple technology. There are a lot of other systems working with bead beating.”

    What’s different about Bertin’s Precellys line of biological sample grinders, she said, is the specific movement of the tubes. In addition to moving up and down they also move on the lateral aspect, making the beads form a figure 8 inside the tube, which allows for more efficient grinding.

    To homogenize tissue, spores, noncultivatable microorganisms, and even viruses, samples are placed in a tube with buffer and beads. Different samples demand different sizes and different material beads—glass, ceramic, or metallic. The 2,000 or so protocols on the Bertin website will also indicate the optimal speed and duration. “If you go too strong or too long, your sample will be damaged and your results will be bad,” Brossard-Desjonqueres noted.

    Mortar and pestle are still used in many R&D labs that don’t have a lot of samples, or that frequently process different samples. “The problem is that it’s not a standardized method, it’s always different from one operator to another one.”

    Earlier this year Bertin launched Minilys, a smaller bead beater-homogenizer, based on the same technology. Minilys can accommodate either three small (0.5 or 2 mL) tubes, or a single 7 mL tube.

    Other models, designed for higher throughput, can handle up to 24 tubes simultaneously. These are available as stand-alone units—which give R&D-type labs flexibility in terms of sample type and size—or integrated into a global solution.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?